Voriconazole MIPD Simulator
Indication: Invasive fungal infections
Interactive voriconazole MIPD simulator for invasive fungal infections. Voriconazole is a triazole antifungal that inhibits fungal CYP51, reducing ergosterol synthesis. This tool implements the Kluwe aggregate nonlinear mixed-effects model plus comparator oral and IV PopPK models to individualize exposure and trough targets during treatment of aspergillosis and other serious mycoses.
Drug Overview
Clinical Context
- Molecular Target
- Fungal CYP51 (lanosterol 14-alpha-demethylase)
- Drug Class
- Antifungal
- Therapeutic Area
- Infectious Disease
- Indication
- Invasive fungal infections
- Route of Administration
- Oral, IV infusion
Model Information
- Model Type
- MIPD / nonlinear PopPK
This simulator was built from published pharmacometric literature using PKPDBuilder's AI-powered model extraction pipeline.
About This Simulator
This interactive pharmacokinetic simulator for Voriconazole MIPD allows you to explore concentration-time profiles under different dosing scenarios. The underlying MIPD / nonlinear PopPK model characterizes the pharmacokinetics of this antifungal following oral, iv infusion administration.
Use the simulator to visualize key exposure metrics including AUC (area under the curve), Cmax (peak concentration), and Ctrough (trough concentration). The pharmacodynamic component links drug exposure to therapeutic or safety endpoints.
Built with PKPDBuilder — an AI-powered platform that transforms published pharmacometric literature into interactive, deployable Shiny applications. No coding required.
Frequently Asked Questions
What does the Kluwe voriconazole MIPD simulator compare?
This page implements the Kluwe et al. real-world evaluation of published voriconazole nonlinear mixed-effects models. The simulator includes an aggregate/hybrid model and comparator M1/M2 models so users can explore how patient covariates, CYP2C19 phenotype, interacting drugs, and route affect voriconazole exposure.
Why is voriconazole model-informed precision dosing useful?
Voriconazole has nonlinear pharmacokinetics, narrow exposure targets, large interindividual variability, CYP2C19 pharmacogenomic effects, and clinically important drug interactions. Model-informed precision dosing helps explore dosing scenarios and trough-target attainment before therapeutic drug monitoring results are available.
What trough range is usually targeted for voriconazole?
Common clinical targets are approximately 1–5.5 mg/L, balancing efficacy at low concentrations against toxicity risk at high concentrations. Exact targets vary by institution, infection severity, pathogen, and patient context; this simulator is for research and education rather than direct clinical dosing.
What is the Voriconazole MIPD PK simulator?
This is a free, interactive pharmacokinetic simulator for Voriconazole MIPD used in Invasive fungal infections. It allows researchers, pharmacologists, and students to explore concentration-time profiles, dosing regimens, and exposure metrics based on published population PK models.
What drug class does Voriconazole MIPD belong to?
Voriconazole MIPD is classified as a Antifungal that targets Fungal CYP51 (lanosterol 14-alpha-demethylase). It is used in the Infectious Disease therapeutic area.
What route of administration does this model simulate?
This simulator models Oral, IV infusion administration of Voriconazole MIPD. The pharmacokinetic parameters (absorption rate, bioavailability, volume of distribution) are specific to this route.
What type of PK model is used?
This simulator uses a MIPD / nonlinear PopPK model. Population PK models account for interindividual variability and covariate effects on drug exposure.
Is this simulator free to use?
Yes, all PKPDBuilder simulators are completely free. They are built from published pharmacokinetic literature and are intended for research and educational purposes. No login is required to run simulations.
Can I use this for clinical dosing decisions?
No. This simulator is for research and educational purposes only. It should not be used for clinical decision-making or patient dosing. Always consult the prescribing information and clinical pharmacology guidelines for therapeutic drug use.
Related Simulators
Vancomycin Hemodialysis PopPK Simulator
Serious gram-positive infections requiring IV vancomycin
Voriconazole
Invasive aspergillosis, candidemia
Oxfendazole Population PK — Tablet Formulation in Healthy African Adults
Onchocerciasis (river blindness)
Shingrix (Recombinant Zoster Vaccine) PK Simulator
Shingles prevention
Prevnar 20 (PCV20) PK Simulator
Pneumococcal disease prevention
Paxlovid (Nirmatrelvir/Ritonavir) PK Simulator
COVID-19 treatment
Ready to Simulate?
Launch the Voriconazole MIPD simulator to explore dosing scenarios and pharmacokinetic profiles interactively.
🚀 Launch SimulatorComments
⚠️ Disclaimer
This simulator is for research and educational purposes only. It is not intended for clinical decision-making, patient dosing, or therapeutic drug monitoring. Pharmacokinetic parameters are derived from published literature and represent population-level estimates. Individual patient pharmacokinetics may differ significantly. Always consult approved prescribing information and qualified healthcare professionals for clinical decisions.
Powered by PKPDBuilder.com • Free pharmacokinetic simulators for the scientific community